{
    "clinical_study": {
        "@rank": "97636", 
        "arm_group": [
            {
                "arm_group_label": "herb and mineral combination product", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will consume 3 herb and mineral combination product softgels daily, 1 softgel immediately before each of the 3 largest meals, throughout the 12-week supplementation period."
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects will consume 3 softgels daily, 1 softgel immediately before each of the 3 largest meals, throughout the 12-week supplementation period"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi-center, randomized, double-blind, placebo-controlled study in approximately\n      104 subjects (52 per group) to evaluate the effectiveness of  an herb and mineral\n      combination product on fasting serum glucose levels in subjects with impaired fasting\n      glucose.  The study consists of 5 visits: a Screening visit, followed by a Baseline visit\n      (at which eligible subjects will be randomized to product to consume throughout the 12-week\n      supplementation period), followed by Supplementation period visits at 3, 6 and 12 weeks\n      after baseline."
        }, 
        "brief_title": "Trial of an Herb and Mineral Combination Product on Fasting Glucose in Adults at Risk for Developing Diabetes", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Prediabetes", 
        "condition_browse": {
            "mesh_term": [
                "Glucose Intolerance", 
                "Prediabetic State"
            ]
        }, 
        "detailed_description": {
            "textblock": "The target population of this clinical trial is otherwise healthy, pre-diabetic adults who\n      present with impaired fasting glucose."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be male or female, at least 18 years of age\n\n          -  If age \u226545 years, must have a body mass index \u2265 25 kg/m2\n\n          -  If age <45 years, must have a body mass index \u2265 25 kg/m2 AND present with at least\n             one additional risk factors for developing diabetes.\n\n          -  Agree to use contraception throughout study period, unless postmenopausal or\n             surgically sterile (women only)\n\n          -  Be able to understand the nature and purpose of the study including potential risks\n             and side effects\n\n          -  Be willing to consent to study participation and to comply with study requirements\n\n          -  Have a finger stick fasting blood glucose between 105 and 140 mg/dL and a serum\n             fasting glucose between 100 and 125 mg/dL, measured at screening\n\n        Exclusion Criteria:\n\n          -  Have diabetes (type I or II) or an HBA1c measurement >6.5% at any time in the past or\n             at the screening visit\n\n          -  Have been taking within 2 weeks of screening  any dietary supplement including\n             vitamin and mineral complexes; herbal supplements; fish oil; fiber supplements; or\n             any herbal ingredient/product that significantly affects glucose metabolism\n\n          -  Have been taking within 4 weeks of screening  any prescription or over-the-counter\n             (OTC) medication that significantly affects glucose  metabolism, including but not\n             limited to, sulfonylureas, meglitinides, biguanides, thiazolidinediones,\n             alpha-glucosidase inhibitors, Inhibitors of dipeptidyl peptidase 4 (DPP-4\n             inhibitors), systemic corticosteroids\n\n          -  Daily use of non-steroidal anti-inflammatory drugs (NSAIDS)  (daily baby aspirin use\n             and continuous use of NSAIDS for 3 days or less for acute aches and pains are\n             acceptable)\n\n          -  Any co-morbidity or treatment that could, in the opinion of the investigator,\n             preclude the subject's ability to successfully and safely complete the study or that\n             may confound study outcomes\n\n          -  Anticipated changes in dietary patterns or physical activity levels during the study,\n             including attempts at body weight reduction\n\n          -  Eating disorder\n\n          -  Polycystic ovary syndrome\n\n          -  Known allergies or intolerance to any substance in the study product\n\n          -  Are pregnant or breastfeeding women\n\n          -  History of alcohol, drug, or medication abuse\n\n          -  Have participated in another study with any investigational product within 1 month of\n             screening\n\n          -  Had a recent (<3 months) gastrointestinal surgery or any planned surgery during the\n             clinical study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "104", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02146157", 
            "org_study_id": "2012110"
        }, 
        "intervention": {
            "arm_group_label": "herb and mineral combination product", 
            "description": "herb and mineral product containing cinnamon, turmeric and holy basil", 
            "intervention_name": "herb and mineral combination product", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 20, 2014", 
        "location": [
            {
                "contact": {
                    "email": "\u2022 annicashumny@radiantresearch.com", 
                    "last_name": "Annica Shumny", 
                    "phone": "312-494-6226"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60610"
                    }, 
                    "name": "Radiant Research"
                }, 
                "investigator": {
                    "last_name": "Kent Kamradt, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "\u2022 gbondurant@ckrainc.com", 
                    "last_name": "Greta BonDurant", 
                    "phone": "859-264-8999"
                }, 
                "contact_backup": {
                    "email": "lcampbell@ckrainc.com", 
                    "last_name": "Leigh Anne Campbell", 
                    "phone": "859-264-8999"
                }, 
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40509"
                    }, 
                    "name": "Central Kentucky Research Associates"
                }, 
                "investigator": {
                    "last_name": "James L Borders", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bingham Farms", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48025"
                    }, 
                    "name": "Quest Research Institute"
                }, 
                "status": "Completed"
            }, 
            {
                "contact": {
                    "email": "\u2022 lindabrotherton@radiantresearch.com", 
                    "last_name": "Linda Brotherton", 
                    "phone": "513-247-5592"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45249"
                    }, 
                    "name": "Radiant Research"
                }, 
                "investigator": {
                    "last_name": "Michael J Noss, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dayton", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45439"
                    }, 
                    "name": "Providence Health Partners Center for Clinical Research"
                }, 
                "status": "Completed"
            }, 
            {
                "contact": {
                    "email": "\u2022 ksmith@mvcresearch.com", 
                    "last_name": "Kristy Smith", 
                    "phone": "864-334-0141"
                }, 
                "facility": {
                    "address": {
                        "city": "Greer", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29651"
                    }, 
                    "name": "Mountain View Clinical Research"
                }, 
                "investigator": {
                    "last_name": "Nancy K Durham, DNP", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled Trial to Assess Efficacy and Tolerability of an Herb and Mineral Combination Product on Fasting Glucose in Adults at Risk for Developing Diabetes", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Fasting glucose will be measured on serum samples obtained at screening (to be used as baseline value) and at day 84", 
            "measure": "Change from Baseline in fasting blood glucose", 
            "safety_issue": "No", 
            "time_frame": "Day 84"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02146157"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Fasting glucose will be measured on serum samples obtained at screening (to be used as baseline value) and at day 42", 
                "measure": "Change from Baseline in fasting serum glucose", 
                "safety_issue": "No", 
                "time_frame": "Day 42"
            }, 
            {
                "description": "Fasting glucose will be measured on serum samples obtained at screening (to be used as baseline value) and at day 21", 
                "measure": "Change from Baseline in fasting blood glucose", 
                "safety_issue": "No", 
                "time_frame": "Day 21"
            }, 
            {
                "description": "Glycosylated hemoglobin (HbA1c) will be measured on whole blood samples obtained at screening and at day 84.", 
                "measure": "Change from Baseline in HbA1c", 
                "safety_issue": "No", 
                "time_frame": "Day 84"
            }, 
            {
                "description": "Total cholesterol, high-density lipoprotein, low-density lipoprotein, very low-density lipoprotein, and triglycerides will be measured on serum samples obtained at screening and at day 84 using a standard lipid panel.", 
                "measure": "Change from Baseline in fasting lipids", 
                "safety_issue": "No", 
                "time_frame": "Day 84"
            }, 
            {
                "description": "Total cholesterol, high-density lipoprotein, low-density lipoprotein, very low-density lipoprotein, and triglycerides will be measured on serum samples obtained at screening and at day 42 using a standard lipid panel.", 
                "measure": "Change from Baseline in fasting lipids", 
                "safety_issue": "No", 
                "time_frame": "Day 42"
            }, 
            {
                "description": "Total cholesterol, high-density lipoprotein, low-density lipoprotein, very low-density lipoprotein, and triglycerides will be measured on serum samples obtained at screening and at day 21 using a standard lipid panel.", 
                "measure": "Change from Baseline in fasting lipids", 
                "safety_issue": "No", 
                "time_frame": "Day 21"
            }, 
            {
                "description": "Body mass index", 
                "measure": "Change from Baseline in BMI", 
                "safety_issue": "No", 
                "time_frame": "Day 84"
            }, 
            {
                "measure": "Change from Baseline in waist-to-hip ratio", 
                "safety_issue": "No", 
                "time_frame": "Day 84"
            }
        ], 
        "source": "NewChapter, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Procter and Gamble", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "NewChapter, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}